AstraZeneca’s Susan Galbraith On What’s Next In The Cancer Pipeline

Success is said to breed success, but for AstraZeneca PLC, recent triumphs for its oncology portfolio are not to be taken for granted. As well as diversifying its pipeline through select deals, such as the just-closed acquisition of TeneoTwo, Inc. to boost its hemato-oncology presence, the company is banking on success with its pipeline of novel anticancers to take its offering to the next level. Oncology R&D chief Susan Galbraith talked to Scrip about some of the more promising earlier candidates coming through the pipeline.

Galbraith joined AstraZeneca back in 2010 when the company was a byword for poor pipeline prospects, and she played a key role in developing AstraZeneca’s oncology strategy as part of the company’s well-documented turnaround. In June 2021, her responsibilities expanded from leading AstraZeneca’s early-stage oncology R&D to include the late-stage pipeline as well following the death of José Baselga earlier that year. (Also see "